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Anaplastic large-cell lymphoma, a T-cell neoplasm, is primarily apediatric disease. Seventy-five percent of pediatric anaplasticlarge-cell lymphoma cases harbor the chromosomal translocation
t(2;5)(p23;q35) leading to the ectopic expression of NPM-ALK, a
chimeric tyrosine kinase. NPM-ALK consists of an N-terminal nucle-
ophosmin (NPM) domain fused to an anaplastic lymphoma kinase (ALK)
cytoplasmic domain. Pediatric NPM-ALK+ anaplastic large-cell lym-
phoma is often a disseminated disease and young patients are prone to
chemoresistance or relapse shortly after chemotherapeutic treatment.
Furthermore, there is no gold standard protocol for the treatment of
relapses. To the best of our knowledge, this is the first study on the
potential role of the microRNA, miR-497, in NPM-ALK+ anaplastic large-
cell lymphoma tumorigenesis. Our results show that miR-497 expres-
sion is repressed in NPM-ALK+ cell lines and patient samples through the
hypermethylation of its promoter and the activity of NPM-ALK is
responsible for this epigenetic repression. We demonstrate that overex-
pression of miR-497 in human NPM-ALK+ anaplastic large-cell lym-
phoma cells inhibits cellular growth and causes cell cycle arrest by tar-
geting CDK6, E2F3 and CCNE1, the three regulators of the G1 phase of
the cell cycle. Interestingly, we show that a scoring system based on
CDK6, E2F3 and CCNE1 expression could help to identify relapsing
pediatric patients. In addition, we demonstrate the sensitivity of NPM-
ALK+ cells to CDK4/6 inhibition using for the first time a selective
inhibitor, palbociclib. Together, our findings suggest that CDK6 could be
a therapeutic target for the development of future treatments for NPM-
ALK+ anaplastic large-cell lymphoma.
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ABSTRACT
Introduction
Anaplastic large cell lymphoma (ALCL) is an aggressive form of T-cell non-
Hodgkin lymphoma (NHL) with a constant membrane expression of the CD30
antigen, a cytokine receptor from the tumor necrosis factor receptor family.
Four distinct entities of ALCL are currently recognized based on the 2016
revised World Health Organization (WHO) lymphoma classification: 1)
anaplastic lymphoma kinase (ALK)-positive(+) ALCL; 2) ALK-negative (ALK–)
ALCL; 3) primary cutaneous ALCL; and 4) breast implant-associated ALCL.1
ALCL accounts for approximately 10-15% of all NHL in children but is rare in
adults (1-2% of adult NHL). Pediatricians have adopted ALCL99 chemotherapy
including low cumulative doses of methotrexate, as standard therapy.2 Patients
with pediatric ALCL have a favorable prognosis; however, systemic ALCL is
often a disseminated disease and pediatric patients are
prone to chemoresistance or to relapse after stopping
the treatment. All relapses occur in patients with
advanced disease and there is still no gold standard for
treating relapses.
In children and adolescents, more than 90% of sys-
temic ALCL cases harbor a chromosomal translocation
t(2;5)(p23;q35) that leads to the expression of the NPM-
ALK chimeric tyrosine kinase. This kinase consists of an
N-terminal  nucleophosmin (NPM) domain fused to the
ALK cytoplasmic domain.3,4 ALK is a tyrosine kinase
receptor whose expression is normally restricted to neu-
ral progenitor cells during development.5 At diagnosis,
ALCL patients are grouped into risk groups based on the
presence of NPM-ALK transcripts in peripheral blood
and/or bone marrow6  and the quantification of anti-ALK
antibody in peripheral blood,7 and chemotherapy treat-
ment is adapted accordingly.
In ALCL, oncogenic NPM-ALK signaling is mediated
by different pathways, such as RAS/ERK and JNK/STAT
pathways, which play major roles in lymphomagenesis
by controlling key cellular processes such as cell cycle
progression.8,9 Studies showed increased proliferation of
Rat1a fibroblasts upon ectopic expression of NPM-ALK
as a consequence of accelerated entry into the S phase of
the cell cycle. Furthermore, this was associated with a
significant upregulation of cyclin A and cyclin D1 and
increased levels of the mitogenic proto-oncogenes Jun,
Fos, and Myc.10 Moreover, in 293T and Jurkat cells, it has
been shown that forced expression of NPM-ALK
induces JNK (JUN N-terminal kinase) and Jun phospho-
rylation, thereby up-regulating the activity of AP1 tran-
scription factors. This results in uncontrolled cell cycle
progression and cell growth due to the downregulation
of p21 and the concomitant upregulation of cyclin A and
cyclin D3.11 The ectopic expression of constitutively
active NPM-ALK in Ba/F3 mouse cells leads to FOXO3A
phosphorylation by Akt, upregulation of cyclin D2
expression and downregulation of p27 and Bim-1
expression to promote cell survival and cell cycle pro-
gression.12 In Ba/F3 mouse cells, NPM-ALK, via the
PI3K/Akt pathway, also controls cell division cycle 25 A
(Cdc25A), a key regulator of the G1 phase and the G1/S
transition.13  
Many microRNAs (miRNAs) modulate several major
proliferation pathways by controlling critical regulators
such as Cyclin-CDK complexes.14  miRNAs are single-
stranded small non-coding RNAs that are pivotal in
physiological and pathological processes such as devel-
opment, cell proliferation and apoptosis. In general, by
binding to specific targets with distinct degrees of com-
plementarity, miRNAs exhibit a negative regulatory role
at the post-transcriptional level through the inhibition of
translation and/or degradation of their messenger RNA
targets. There is growing evidence to show that differ-
entially expressed miRNAs are associated with tumor
types and cancer development.15 Indeed, several
miRNAs display defective expression patterns in
tumors, consequently altering oncogenic or tumor sup-
pressive targets. miRNAs such as miR-16, miR-17-92,
miR-21, miR-26a, miR-29a, miR-96, miR-101, miR-
135b, miR-146a, miR-150, miR-155 and miR-219 are
dysregulated and serve as oncogenes or tumor suppres-
sors in NPM-ALK+ ALCL.16-20 Most of these miRNAs
have been found to be down-regulated (miR-16, miR-21,
miR-26a, miR-29a, miR-96, miR-101, miR-146a, miR-
150, miR-155 et miR-219) in NPM-ALK+ ALCL. Our lab-
oratory showed, for the first time, that NPM-ALK+
ALCL cell lines and primary tissues express low levels of
several miRNAs mediated by the hypermethylation of
their gene promoter.17,21 Both NPM-ALK and STAT3
activities contributed to epigenetic silencing in NPM-
ALK+ ALCL cell lines and biopsy specimens by up-regu-
lating and recruiting DNMT1 to the promoter of miR-
29a, miR-125b and miR-150.17,19,21 The repressive methy-
lation catalyzed by DNMT1 can be partially reversed by
treatment with 5-aza-2’-deoxycytidine (5-aza-dC,
decitabine, Dacogen,® SuperGen Inc., Dublin, CA,
USA), a DNMT inhibitor. This DNA-demethylating
agent has been shown to restore miR-497 expression,
which is suppressed in HT29 colorectal cancer cells.22 In
addition, miR-497 downregulation has been consistent-
ly demonstrated in a variety of solid tumor types such as
hepatocellular carcinoma, ovarian cancer, colorectal ade-
nomas, and in multiple myeloma cells.22,23 MiR-497, a
highly conserved miRNA encoded by the first intron of
the MIR497HG gene on human chromosome 17p13.110
belongs to the miR-15/16 family (miR-15a, miR-15b,
miR-16-1/2, miR-195, miR-424 and miR-497) sharing
the same seed sequence AGCAGCA.24  Downregulation
of miR-497 controls cell cycle progression by regulating
cell cycle regulators such as Cyclin A2, Cyclin D1,
Cyclin D2, Cyclin D3 and Cdc25a. In a previous study,
using microarray miRNA-expression profiling, we
showed that miR-195 and miR-497 was differentially
expressed  in NPM-ALK+ ALCL lymph node primary tis-
sues compared to reactive lymph nodes of healthy
donors.21 As miR-195 and miR-497 are encoded as a
cluster within the same host gene, MIR497HG (a highly
conserved miRNA cluster),25 we sought to simultane-
ously study the roles of miR-195 and miR-497 in NPM-
ALK+ ALCL tumorigenesis. Accordingly, we measured
miR-195 and miR-497 expression in human NPM-ALK+
ALCL primary biopsies and cell lines. First, we studied
the biological functions of these miRNAs in human
NPM-ALK+ ALCL cells. We showed that overexpression
of miR-497 inhibits cellular growth and causes cell cycle
arrest. We identified cyclin E1, E2F3 and CDK6 as the
main miR-497-targets responsible for the observed phe-
notype. Several CDK4/6 inhibitors have been developed
[PD-0332991/palbociclib (Pfizer), LEE011/ribociclib
(Novartis), and LY2835219/abemaciclib (Lilly)] and are
currently being tested in clinical trials for patients with
solid tumors and B lymphomas.26 Previous studies have
demonstrated that palbociclib caused cycle arrest and
apoptosis in T-cell leukemia in vitro and delayed disease
progression in mouse models of T-cell acute lym-
phoblastic leukemia.27  However, this class of drugs has
not been tested in T-cell lymphomas. Thus, we demon-
strate, for the first time, the sensitivity of NPM-ALK+
cell lines to  CDK4/6 inhibition using palbociclib.
Furthermore, we show that a scoring system based on
CDK6, E2F3 and CCNE1 expression could help identify
relapsing patients with a very short survival. Altogether,
our results indicate that miR-497 functions as a tumor
suppressor and that some of the miR-497 functional
downstream targets could be used as predictors of clini-
cal outcomes. Amongst them, CDK6 could be a thera-
peutic target for the development of future treatments
for NPM-ALK+ ALCL.
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Methods
Human cell lines, tumoral and normal samples
The two human NPM-ALK+ ALCL cell lines,  KARPAS-299
and SU-DHL1, were obtained from DSMZ (German Collection
of Microorganisms and Cell Culture, Braunschweig, Germany).
The COST cell line was established in our laboratory.28 CD4+
cells were stimulated for two days using CD3/CD28 antibodies
coupled to magnetic beads (Dynabeads, Invitrogen, Waltham,
USA) in RPMI-1640 with 20% fetal calf serum (FCS). All cells
were cultured in RPMI-1640 supplemented with 10% FCS
(KARPAS-299 and COST) or 15% FCS (SU-DHL1) supplement-
ed with 2 mM L-glutamine, 1 mM sodium pyruvate, and 100
U/mL penicillin/streptomycin (all from Invitrogen, Waltham,
USA). Cells were cultured at 37°C with 5% CO2 and maintained
in exponential growth phase. Tumor samples from NPM-ALK+
and NPM-ALK– ALCL diagnosed based on morphological and
immunophenotypical criteria (according to the last WHO classi-
fication) were obtained from our tumor tissue bank. Only cases
with at least 50% lymph node involvement (assessed by CD30
staining of frozen biopsies) and good RNA integrity were select-
ed from our tumor bank. Studies were conducted in accordance
with the Declaration of Helsinki, and with the approval of  the
relevant ethics committees. Lymph nodes collected from
patients with reactive non-malignant disease, who were consid-
ered to be healthy donors, were retrieved from the CRB-Cancer
du CHU de Bordeaux n. BRIF BB-0033-00036, a member of the
“Cancéropôle Grand Sud-Ouest” network.
Cell treatment
Anaplastic large cell lymphoma cell lines were treated with 2
µM decitabine (Sigma-Aldrich, Saint Quentin Fallavier, France)
for four days [fresh drug was added at 48 hours (h)] and NPM-
ALK activity was inhibited using 500 nM crizotinib
(@rtMolecule, Poitiers, France) for three days. ALCL cell lines
were treated with 1 mM of PD-0332991 (Selleck Chemicals,
Houston, TX, USA) during 24 h.
MiRNA and siRNA transfections
siRNAs (si-CDK6, si-CCNE1, si-CDC25A and si-STAT3) at
0.5 nmol, si-E2F3 (Online Supplementary Table S1) at 1 nmol or
miRNA mimics (miR-497-5p: mirVana MC10490 and miR-CTL:
mirVana AM17110, Invitrogen, Waltham, USA) were transfect-
ed by electroporation according to a previously described proce-
dure.17 In the case of co-transfection of several siRNAs, 0.2 nmol
of each si-CDK6 and si-CCNE1 and 1 nmol of si-E2F3 were
used. The same amount of duplex siRNA (Eurogentec, Angers,
France) was transfected and used as negative control.
Purification of biotinylated-miRNA containing 
complexes
Five million KARPAS-299, COST and SU-DHL1 cells were
transfected with 0.25 nmol of biotinylated hsa-miR-497-5p (hsa-
miR-497 mercury LNA miRNA mimics premium) or biotinylat-
ed-irrelevant miRNA (negative control) (Exiqon, Vedbaek,
Denmark). Total cell lysates, 24 h post transfection, were pre-
pared in IP-buffer: 25 mM Tris-HCl pH 7.5, 200 mM NaCl, 0.2%
Triton-X100, 5 mM MgAc, 1 mM DTT, protease inhibitors
(Roche France, Meylan, France) and 0.2 U/mL RNase OUT
(Invitrogen, Waltham, USA). The lysates were incubated for 2 h
with streptavidin coupled to magnetic beads (Thermofisher,
Waltham, USA) previously saturated with 0.5 mg/mL BSA and
0.2 mg/mL yeast tRNA. Purified RNAs were recovered after 5
washes with IP buffer by Trizol reagent-mediated extraction
(Invitrogen, Waltham, USA), according to the manufacturer’s
instructions. RNA was reverse transcribed using SuperScript III
Reverse Transcriptase (Invitrogen, Waltham, USA) and subjected
to quantitative PCR. Biotin pull-down efficiency was expressed
as a percentage of input. GAPDH amplification was used to
remove pull-down background. The specificity of purification
was evaluated for each putative target based on the enrichment
in the Biotin-miR-497 condition relative to Biotin-CTL.
RNA extraction, reverse transcription and quantitative
PCR
Total RNA from cell lines and CD4+ cells were extracted using
the Trizol reagent (Invitrogen, Waltham, USA), according to the
manufacturer’s instructions. MiRNAs were reverse transcribed
using the Universal cDNA Synthesis Kit II (Exiqon, Vedbaek,
Denmark). The expression of miR-195, miR-497, RNU1A1 and
SNORD44 (used as reference genes) was measured by quantita-
tive PCR (qPCR) using a specific Exiqon PCR primer set and
SYBR qPCR Premix Ex Taq (Tli RNaseH Plus) Kit (Takara Bio
Europe, Saint-Germain-en-Laye, France). Messenger RNAs
(mRNAs) were reverse transcribed using Primescript RT reagent
kit (Takara Bio Europe, Saint-Germain-en-Laye, France), accord-
ing to the manufacturer’s recommendations. qPCR was per-
formed using the primers listed in Online Supplementary Table S1.
Protein extraction and Western blotting analyses
Total cell lysates were prepared by incubating ALCL cells in
Laemmli 1X buffer (Bio-Rad, Marnes-la-Coquette, France) for 10
minutes (min) on ice. Cells were then subjected to sonication
using a Bioblock Vibra-cell 72446 apparatus at 35% of its power
(Fisher Scientific, Illkirch, France). Proteins were separated by
electrophoresis on SDS-polyacrylamide gels and electroblotted
onto nitrocellulose membrane (GE Healthcare Europe, Velizy-
Villacoublay, France). Proteins of interest were detected using
primary antibodies [(CDC25A 1/500: sc-7389, CDK6 1/2000:
CST#3136, CCNE1 1/2000: sc-247, E2F3 1/2000: GTX102302,
CDK4 1/2000: sc-260, Rb 1/2000: OP66, phosphor-Rb (ser780)
1/2000: CST#9307)] and HRP -conjugated anti-mouse (Promega,
Madison, USA) or anti-rabbit secondary antibodies (Cell
Signaling Technology, Danvers, USA). Densitometric analysis
was performed using ImageJ software.29 
Cell proliferation assays and cell cycle analysis 
Cell proliferation was evaluated using CellTiter 96AQueus One
Solution (Promega, Madison, USA) and cell counting. For cell
cycle analysis, NPM-ALK+ ALCL cells were washed with PBS and
fixed overnight at 4°C in 70% ethanol. Cells were then washed
with PBS supplemented with 0.1% BSA and incubated for 30 min
with 10 mg/mL propidium iodide (Invitrogen, Waltham, USA) and
500 mg/mL of RNAse (Sigma-Aldrich, Saint Quentin Fallavier,
France). Thereafter, cells were analyzed with a flow cytometer 
MACSQUANT VYB (Miltenyi, Paris, France).
Apoptosis luminescent assay
The Caspase-Glo® 3/7 Assay Kit (Promega, Madison, WI,
USA) was used to assess cell apoptosis, according to the manu-
facturer’s instructions.
Bisulfite conversion and DNA methylation analysis
Genomic DNA was bisulfite converted using the MethylEdge
Bisulfite Conversion System (Promega, Madison, USA) follow-
ing the manufacturer’s protocol. The region of interest was
amplified by PCR and methylation level was measured by
pyrosequencing using PyromarkQ24 (Qiagen France,
Courtaboeuf, France). (Primers are listed in Online Supplementary
Table S1).
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Xenograft tumor assay
Mice were housed under pathogen-free conditions in an animal
room at constant temperature (20-22°C), with a 12 h/12 h
light:dark cycle and free access to food and water. All animal pro-
cedures were performed following the principle guidelines of
INSERM, and our protocol was approved by the Midi-Pyrénées
Ethics Committee on Animal Experimentation. ALCL cell lines
were transfected either with control (miR-CTL) or miR-497
miRNA mimics. Twenty-four hours later, a total of 3x106 COST or
KARPAS-299 cells or 2x106 SU-DHL1 cells were injected subcuta-
neously into both flanks of 7-week old female non-obese diabet-
ic/severe combined immunodeficient (NOD-SCID) or NOD-
SCID Gamma (NSG) mice (Janvier Labs, Le Genest, St Isle,
France). Mouse body weight and tumor volumes were measured
three times a week with calipers, using the formula “length x
width2 x π/6”. At the end of the experiment, mice (6 per group)
were humanely sacrificed. Subcutaneous tumors were then
excised and sections were fixed in 10% neutral buffered formalin
for histochemical analysis.
RNA sequencing
RNA sequencing was performed at the LISBP, Toulouse, France,
on an Ion Proton (Thermofischer, Waltham, MA, USA) as single-
end oriented 95pb-long reads. RNAs co-purified with biotinylated
hsa-miR-497-5p or with a biotin-negative control mimic (biotin-
miR-CTL) were used for library preparation using the Ion Total
RNA-seq Kit V2 and Ion PI HiQ OT2 Kit (Thermofischer,
Waltham, MA, USA). TopHat2 (v.2.1.0) was used for sequence
alignment on the human genome GRCH38.83 and counting reads
performed using HTSeq-Count (v.0.6.1P1).
Statistical analysis 
Results are presented as mean values±Standard Error of Mean
(SEM) from at least 3 independent experiments unless otherwise
indicated. Differences between groups were examined using the
unpaired two-tailed Student’s t-test, unpaired two-tailed Student’s
t-test with Welch’s correction or two-way ANOVA with
Bonferroni post-test using GraphPad Prism software version 6.00
for Windows (GraphPad software) (La Jolla, CA, USA). For all
tests, P<0.05 (*), P<0.01 (**) or P<0.001 (***) were considered sta-
tistically significant. Event-free survival was analyzed using a
Receiver Operating Characteristics (ROC) method. A cut-off value
was then chosen which would assume a minimum error rate and
a limited number of misclassifications within the cohort.
Results
The miR-497∼195 cluster is down-regulated in human
NPM-ALK+ primary lymphoma samples and cell lines 
To determine the profile of methylated miRNA genes
driven by NPM-ALK oncogene in ALCL cells, we per-
formed a high throughput analysis of miRNA expression
(small RNA sequencing) from NPM-ALK+ KARPAS-299
cells following decitabine treatment or transfection with a
siRNA targeting ALK mRNA (si-ALK). A set of 13 miRNAs
(miR-9-5p, miR-1287-5p, miR-15a-5p, miR-22-3p, miR-
26a-5p, miR-29c-3p, miR-194-5p, miR-195-5p, miR-199a-
3p, miR-199a-5p, miR-223-3p, miR-3613-5p and miR-497-
5p) was found to be up-regulated >1.5-fold in treated cells
in both conditions (si-ALK and decitabine) compared
either to negative control siRNA (si-CTL) or drug vehicle
alone (DMSO) (Figure 1A). Amongst these 13 miRNAs,
using microarray data previously published of miRNA-
expression of NPM-ALK+ (n=52) and NPM-ALK– (n=5)
ALCL patients,21 we observed that miR-195 and miR-497
were down-regulated only in NPM-ALK+ ALCL patients
compared to normal reactive lymph node (RLNs, n=3)
(Online Supplementary Table S2). To corroborate the
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Figure 1. MiR-195 and miR-497 are down-regulated in human NPM-anaplastic lymphoma kinase (ALK)-positive(+) primary lymphoma samples and cell lines. (A)
RNA sequencing from NPM-ALK+ KARPAS-299 cells following decitabine or DMSO treatment or transfection with a control siRNA (si-CTL) or siRNA targeting ALK mRNA
(si-ALK). A set of 13 miRNAs was found to be up-deregulated >1.5 fold in treated cells in both conditions (si-ALK and decitabine) compared to either negative control
siRNA (si-CTL) or drug vehicle alone (DMSO). (B) Quantitative real-time PCR (qRT-PCR) analysis of miR-195 and miR-497 in NPM-ALK+ anaplastic large cell lymphoma
patients (n=52). Data were normalized against equivalent miRNA levels from reactive lymph node (RLN) tissue samples (n=19). Data represent means±Standard
Error of Mean (bars), ***P<0.0001; unpaired two-tailed Student’s t-test with Welch’s correction.
A
B
miRNA array data, we performed qPCR analysis for miR-
195 and miR-497 on 23 samples from NPM-ALK+ by
selecting cases with at least 50% lymph node involvement
compared to 12 RLNs (Figure 1B). Significant downregula-
tion of both miR-195 and miR-497 was confirmed in pri-
mary biopsies despite the presence of a mixed population
of neoplastic and normal cells (Figure 1B).
NPM-ALK activity and DNA methylation mediate 
silencing of miR-195 and miR-497 in lymphoma cells
The downregulation of miR-195 and miR-497 observed
in  NPM-ALK+ cells suggests that the NPM-ALK+ protein
itself might drive this phenomenon. This hypothesis is
corroborated by the fact that, in our initial screen, miR-
195 and miR-497 were up-regulated following NPM-ALK
knockdown in KARPAS-299 cells (Figure 1A). To verify
whether NPM-ALK is involved in miR-195 and miR-497
silencing, NPM-ALK expression was knocked down in 2
other human NPM-ALK+ ALCL cell lines (COST and SU-
DHL1) using siRNA directed against ALK mRNA (Figure
2A and D). This was followed by reducing NPM-ALK
activity with crizotinib treatment, a pharmacological
inhibitor of ALK tyrosine kinase activity (Figure 2B and
E). Western blotting analysis (Online Supplementary Figure
S1A and B) showed that NPM-ALK was down-regulated
and inhibited. Both inhibition of ALK gene expression
and its activity induce a significant increase in both miR-
195 and miR-497 expression in NPM-ALK+ cells (Figure
2A-E). Next, we measured the levels of both miR-195 and
miR-497 after decitabine treatment in order to confirm
that the observed miR-195 and miR-497 downregulation
in NPM-ALK+ lymphoma cells was, indeed, due to DNA
methylation (Figure 2C and F). We detected a significant
increase in miR-195 and miR-497 expression in DNMT
inhibitor-treated cells compared to the drug vehicle alone
(DMSO) in all NPM-ALK+ cell lines (Figure 2C and F).
STAT3 appears to be implicated in this mechanism (data
not shown). To determine the DNA methylation status of
the MIR497HG promoter, the miR-195 and miR-497 host
gene on chromosome 17, we carried out bisulfite
sequencing analysis of genomic DNA isolated from the
three NPM-ALK+ cell lines: KARPAS-299, SU-DHL1 and
COST and normal CD4 T lymphocytes expressing CD30
antigen activated using CD3/CD28 antibodies (n=3)
(Online Supplementary Figure S2A). The results showed sig-
nificantly high levels of methylation of all CpGs located
in the region upstream of miR-195 and miR-497 promot-
ers in the KARPAS-299 and SU-DHL1, and a few CpGs
(CpG1, CpG2 and CpG3) in COST tumor cells. We
observed lower levels of CpG methylation in the region
upstream of miR-195 and miR-497 promoters in normal
cells (Online Supplementary Figure S2B). Decitabine signifi-
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Figure 2. NPM-anaplastic lymphoma kinase (ALK) activity and DNA methylation mediate downregulation of miR-195 and miR-497. Quantitative RT-PCR analysis
of miR-195 and miR-497 expression in NPM-ALK-positive lymphoma cell lines, COST, KARPAS-299 (KARPAS) and SU-DHL1, transfected with either an irrelevant siRNA
as the negative control (si-CTL) or a siRNA targeting ALK mRNA (si-ALK) (A and D) or treated for 72 hours (h) or not (PBS) with crizotinib (B and E) or treated for 96
h or not (PBS) with decitabine (C and F). SNORD44 was used as an internal control and the relative ratio of miR-195 and miR-497 expression was expressed as 2–
ΔΔCt relative to untreated cells. Data represent means±Standard Error of Mean  (bars) from 3 independent experiments, **P<0.01;  ***P<0.0001; unpaired two-
tailed Student’s t-test with Welch’s correction.
A B C
D E F
cantly decreased methylation levels of CpGs in NPM-
ALK+ cancer cells (Online Supplementary Figure S2C).
Collectively, these data suggest that the silencing of both
miR-195 and miR-497 is due, at least in part, to NPM-ALK
expression and aberrant MIR497HG promoter methyla-
tion in ALCL cells.
Forced expression of miR-497 suppresses cell cycle
progression and prevents the growth of NPM-ALK+ ALCL
cells
To investigate possible biological functions (potential
effects on cell proliferation) of miR-195 and miR-497 in
NPM-ALK+ cells, the two miRNAs were ectopically
C. Hoareau-Aveilla et al.
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Figure 3. Overexpression of miR-497 reduces in vitro viability and growth of NPM-anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells. Cell viability deter-
mined by MTS assay of NPM-ALK+ lymphoma COST, KARPAS-299 (KARPAS) and SU-DHL1 cells 72 hours (h) after transfection with mimic miR-195 (miR-195) (A) or
mimic miR-497 (miR-497) (B). Data represent means±Standard Error of Mean  (bars) from 3 independent biological replicates, ***P<0.0001; unpaired two-tailed
Student’s t-test with Welch’s correction.
Figure 4. Ectopic expression of miR-497 induces cell cycle arrest and reduces growth in vivo of NPM-anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells.
NPM-ALK+ ALCL COST, KARPAS-299 (KARPAS) and SU-DHL1 cells were transfected with negative control miRNA (miR-CTL) or mimic miR-497 (miR-497). Cell cycle
was analyzed (A) and caspase 3/7 activity was measured (B). Data were normalized against the miR-CTL condition. Each experiment was repeated 3 times. (C) NPM-
ALK+ COST, KARPAS-299 (KARPAS) and SU-DHL1 cells transfected either with miR-CTL or miR-497 were injected subcutaneously in the left or right flank of immuno-
deficient mice, respectively (n=6). Tumor volume was evaluated over time by caliper measurements. Data represent mean±Standard Error of Mean, *P<0.05;
**P<0.001; ***P<0.0001;  ns: not significant; unpaired two-tailed Student’s t-test with Welch’s correction. (D) Micrographs of hematoxylin & eosin staining of
excised miR-CTL or miR-497 tumors (original magnification x40). Arrows indicate cells with phenotypical hallmarks of cellular degeneration.
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expressed by transfecting synthetic mimics into KARPAS-
299, SU-DHL1 and COST cell lines. We observed that
upregulation of miR-195 by transfection with miR-195
mimic does not impair cell viability of NPM-ALK+ cells
(Figure 3A). By contrast, upregulation of miR-497 signifi-
cantly affects cell viability of the three cell lines (Figure
3B). The successful overexpression of miR-497 and of
miR-195 were confirmed by qPCR (Online Supplementary
Figure S3). Taken together, these data suggest that only
miR-497 in the miR-497/miR-195 cluster plays a role in
cell proliferation of NPM-ALK+ cells.
Since cell proliferation is closely associated with cell
cycle control and progression, we performed flow cyto-
metric analysis of cell cycle with propidium iodide DNA
staining to examine the effects of miR-497 on cell cycle
distribution in all three NPM-ALK+ cell lines.
Accumulation in the G1 phase of the cell cycle was signif-
icant in KARPAS-299 cells, 48 h post transfection with
miR-497 compared with those transfected with miR-CTL
(Figure 4A). In addition, in the same condition, ectopic
expression of miR-497 in COST and SU-DHL1 cells led to
a significant accumulation of cells in a sub-G1 phase of cell
cycle suggesting cell death (Figure 4A). To test whether
apoptosis is involved in the growth inhibition caused by
miR-497 overexpression, we measured caspase 3 and 7
activity. As shown in Figure 4B, compared to that of miR-
CTL, miR-497 overexpression induced activation of apop-
tosis pathways in COST and SU-DHL1 cells (2.2- and 4-
fold, respectively) but not in KARPAS-299 cells. These
findings suggest that miR-497 overexpression induces
growth-inhibitory effects on cancer cells by impeding cell
cycle progression and leads to programmed cell death. We
next investigated the effect of miR-497 transfection on
tumor growth of NPM-ALK+ cell lines KARPAS-299, SU-
DHL1 and COST in vivo. MiR-CTL or miR-497-transfected
NPM-ALK+ cells were inoculated subcutaneously into the
left or right flanks of each immunodeficient mouse,
respectively (n = 6 for each condition). MiR-497-transfect-
ed NPM-ALK+ cells resulted in significant reduction of
tumor growth (Figure 4C) when compared to those trans-
fected with miR-CTL. Morphological analyses showed
that forced expression of miR-497 in NPM-ALK+ cells
caused phenotypic hallmarks of cellular degeneration
(uncommon chromatin condensation, nuclear piknosis,
decreased cellular volume and disruption of the nuclear
envelope) (Figure 4 D).These results show that miR-497
overexpression drastically reduces the growth of NPM-
ALK+ cells in vivo. Taken together, these experiments sug-
gest a tumor-suppressive function of miR-497 in NPM-
ALK+ cells.
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Figure 5. MiR-497 targets G1/S regulators in anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells. (A) mRNA targets of miR-497 identification workflow.
NPM-ALK+ KARPAS-299 cells transfected with biotinylated forms of human miR-497 (biotin-miR-497) or an irrelevant biotin-miRNA as negative control (biotin-miR-
CTL) were used to co-purify associated mRNAs (enrichment ratio >1.5). Validated candidate targets of miR-497 were collected from miRTarBase (n=77) and experi-
mentally validated miR-497 associated with the regulation of cell cycle from miRSystem database (n=16). CCNE1, CDC25A, CDK6, CCND3 and E2F3 were the only
genes identified in the two computational analyses. (B) Microarray analysis of CCNE1, CDC25A, CDK6, CCND3 and E2F3 mRNA expression in human NPM-ALK+
(n=56; Daugrois et al.,  submitted publication). Data were normalized against equivalent miRNA levels from reactive lymph (RLN) node tissue samples (n=3). Data
represent means±Standard Error of Mean  (bars), *P<0.05; **P<0.001; ***P<0.0001; unpaired two-tailed Student’s t-test with Welch’s correction. (C) Quantitative
real-time PCR (qRT-PCR) analysis of CCNE1, CDC25A, CDK6, CCND3 and E2F3 mRNA was performed after pulldown of the biotinylated miRNAs using streptavidin
beads. The results are presented as the relative enrichment in miR-497 pulldown compared to miRNA control pulldown (enrichment ratio >2).
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Effect of miR-497 on the expression of cell cycle 
regulatory genes in NPM-ALK+ lymphoma cells 
To determine the mechanism(s) by which miR-497 reg-
ulates tumor growth and progression of NPM-ALK+ can-
cer cells, we searched for mRNA targets of miR-497. To
capture miR-497 associated mRNAs, KARPAS-299 cells
were transfected with biotinylated human miR-497. We
isolated and sequenced RNAs that co-purified with
biotin-miR-497 mimic to map miR-497-mRNA interac-
tion. As a negative control, we performed the same exper-
iment with a biotin-negative control mimic (biotin-miR-
CTL). A large set of mRNAs is regulated by miR-497
(enrichment ratio >1.5). In this data set, 77 validated can-
didate targets of miR-497 were collected from the
miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/, Release 7.0)
(Figure 5A). In addition, using the miRSystem database
(http://mirsystem.cgm.ntu.edu.tw/), we identified 16 miR-
497 mRNA targets, experimentally validated and associ-
ated with cell cycle regulation  (KEGG pathway database)
(Figure 5A). We identified 5 mRNA gene targets that were
common to both databases: CCNE1, CDC25A, CDK6,
CCND3 and E2F3 (Figure 5A). Next, we used gene
expression array data (Daugrois et al., 2018, submitted
publication) to identify the veracity of these 5 targets cap-
tured by biotin-miR-497. Despite the presence of a mixed
population of neoplastic and normal cells, CCNE1,
CDC25A, CDK6 and E2F3 mRNAs were found to be sig-
nificantly over-expressed in NPM-ALK+ ALCL patients
(n=55) compared to reactive lymph node controls (RLN)
(Figure 5B). As previously reported by Thompson et al.,
CCND3 was not over-expressed in  NPM-ALK+ ALCL
patients.30 Finally, to validate the specificity of the biotin
pulldown and applicability to other cell lines, biotinylated
forms of miR-497 or negative miRNA-control were used
to co-purify CCNE1, CCDN3, CDC25A, CDK6 and E2F3
mRNAs in three KARPAS-299, SU-DHL1 and COST cell
lines. Enrichment of target mRNAs by streptavidin-medi-
ated purification (enrichment ratio >2) was measured by
qPCR and normalized to miR-CTL enrichment. In the
biotin-miR-497 pulldown of COST, SU-DHL1 and
KARPAS-299 cells, CDC25A, CCNE1 and E2F3 tran-
scripts but not CCDN3 were captured 24 h after transfec-
tion (Figure 5C). Moreover, biotin pulldown enriches
CDK6 mRNA in COST and SU-DHL1 cells but not in
KARPAS-299 cells (Figure 5C). This result was in accor-
dance with data published by Nagen et al.,31 who reported
very weak CDK6 expression in KARPAS-299 cells com-
pared to SU-DHL1 cells (Online Supplementary Figure S5).
Moreover, for the first time, we observed that CDK6 pro-
tein is over-expressed in COST cells (similar to SU-DHL1
cells) in comparison to KARPAS-299 cells (Online
Supplementary Figure S4). To corroborate the results of
miR-497–bound mRNAs capture and transcriptomic
analyses, the effect of miR-497 on the endogenous
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Figure 6. CDK6, CDC25A, CCNE1 and E2F3 are target genes of miR-497 in anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells. (A) Quantitative real-time
(RT)-PCR analysis of CDK6, CDC25A, CCNE1 and E2F3 mRNA expression in NPM-ALK+ lymphoma COST, KARPAS-299 (KARPAS) and SU-DHL1 cells transfected with
negative control miRNA (miR-CTL) or a mimic miR-497 (miR-497). GAPDH was used as internal control and the relative ratios of mRNA expression was expressed as
2–ΔΔCt relative to those in cells transfected with miR-CTL. Data represent means±Standard Deviation (bars), **P<0.001; ***P<0.0001; unpaired two-tailed Student’s
t-test with Welch’s correction. (B) Western blotting analysis of CDK6, CDC25A, CCNE1 and E2F3 expression in NPM-ALK+ COST, KARPAS-299 (KARPAS) and SU-DHL1
cells transfected by mir-CTL or mir-497. The GAPDH protein served as an internal control to ensure equal loading. Results from one representative experiment are
shown. (C) Densitometric analysis was performed using ImageJ software from Wayne Rasband (NIH). The relative levels of the proteins of interest were normalized
to GAPDH levels. Data represent means±Standard Error of Mean  (bars) from 3 independent experiments, **P<0.001; ***P<0.0001;  ns: not significant; unpaired
two-tailed Student’s t-test with Welch’s correction. 
expression of CCNE1, CDC25A, CDK6 and E2F3 was
subsequently examined using qPCR and Western blot-
ting. Transfection of miR-497 mimic induced a significant
decrease of all four mRNAs in all three cell lines com-
pared to cells transfected with miR-CTL (Figure 6A).
Overexpression of miR-497 significantly down-regulated
the protein level of CDK6, CDC25A and E2F3 in all three
cell lines (Figure 6B). In addition, CCNE1 expression was
down-regulated in KARPAS-299 cells but not in COST or
SU-DHL1 cells (Figure 6B). Densitometric analysis of the
mean relative intensity for each target protein of miR-497
supports the Western blotting results (Figure 6C). Taken
together, these results strongly suggest that miR-497 reg-
ulates the expression of CCNE1, CDC25A, CDK6 and
E2F3 in NPM-ALK+ cells.
Significance of identified miR-497 target genes 
in NPM-ALK+ lymphoma cells
To evaluate whether CCNE1, CDC25A, CDK6 and
E2F3 may be functional downstream targets of miR-497
and involved in regulation of NPM-ALK+ cell proliferation,
we individually knocked down the expression of these
genes using specific siRNAs. In order to check that the
knockdown of gene expression had been efficiently
achieved, we performed qPCR and Western blotting to
detect the mRNA (Online Supplementary Figure S5A) and
protein (Online Supplementary Figure S5B) levels, respec-
tively. Densitometric analysis of the mean relative intensi-
ty for each target protein of miR-497 supports the Western
blot results (Online Supplementary Figure S5C). We
observed that, in SU-DHL1 cells, silencing of CDK6
mRNA simultaneously induced a decrease of cell viability
and an increase of both subG1 fraction and caspase 3/7
activity, thereby inhibiting cell growth (Figure 7A-C).
Hence, CDK6 silencing alone is sufficient to recapitulate
the phenotype observed upon miR-497 ectopic expression
in SU-DHL1 cells. These results are similar to those pub-
lished by Nagen et al.31 showing an addiction to CDK6
expression for proper cell cycle progression in this cell line.
In contrast, even though siRNA directed against CDK6 led
to a significant accumulation of COST and KARPAS-299
cells in G0/G1 phase (Online Supplementary Figure S6B and
E), it is not sufficient to fully recapitulate miR-497-induced
blockage of cell cycle. The same observation was made
after E2F3 and CCNE1 mRNA downregulation (Online
Supplementary Figure S6A and D, and C and F, respective-
ly). Finally, we observed that CDC25A knockdown did
not modify the cell cycle profiles of COST and KARPAS-
299 cells (data not shown). We also tested the effect of each
siRNA on cellular apoptosis in COST and KARPAS-299
cells. Compared to the control condition (si-CTL), CDK6
and CCNE1 silencing induced apoptosis in COST cells
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Figure 7. Silencing of CDK6, CCNE1 and E2F3 genes reduces cell proliferation in anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells. NPM-ALK+ ALCL
SU-DHL1 (A-C), COST (D-F) and KARPAS-299 (KARPAS) (G-I) cells were transfected with either an irrelevant siRNA as the negative control (si-CTL) or a siRNA targeting
CDK6 mRNA (si-CDK6) or CDK6, CCNE1 and E2F3 mRNA together (si-Pool). Cell cycle distribution (A, D and  G), cell count at three different time points (0, 1, 2 days)
(B, E and  H) and caspase 3/7 activity (C, F and I) were measured. Data represent means±Standard Error of Mean (bars) from 3 independent experiments, *P<0.05;
**P<0.001; ***P<0.0001;  ns: not significant; unpaired two-tailed Student’s t-test with Welch’s correction.
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but, as expected, not in KARPAS-299 cells (Online
Supplementary Figure S7). In addition, the silencing of E2F3
mRNA did not affect caspase activity in both NPM-ALK+
COST and KARPAS-299 cells (Online Supplementary Figure
S7). Moreover, regardless of the siRNA transfected, cell
viability following RNAi delivery was never significantly
modified in NPM-ALK+ cells (data not shown). Thus, indi-
vidual silencing of three miR-497-targets, CDK6, CCNE1
and E2F3, can reproduce (only to a lesser extent) the miR-
497-induced phenotype (Figure 4A and B). Consequently,
in order to improve the effects observed in COST and
KARPAS-299 cells, we decided to pool siRNAs targeting
CCNE1, CDK6 and E2F3. We transfected KARPAS-299 or
COST cells with siRNAs (pools of three siRNAs/targets)
targeting each of the miR-497-down-regulated transcripts.
In order to check whether the knockdown of gene expres-
sion had been efficiently achieved, we performed qPCR to
detect the mRNA (Online Supplementary Figure S8). We
then analyzed transfected cells for their cell cycle distribu-
tions. Similar to transfection of miR-497 mimics, siRNA
pools induced significant accumulation of KARPAS-299
and COST cells in G0/G1 fraction (Figure 7D and G). Of
note, the same result was observed in COST and SU-
DHL1 cells, 24 h post transfection with the miR-497
mimic (Online Supplementary Figure S9A and B). The reduc-
tion in cell proliferation in the knockdown NPM-ALK+
cells was observed by cell counting (Figure 7E and H). In
addition, compared to the control condition (si-CTL),
CCNE1, CDK6, E2F3 silencing induced apoptosis in
COST cells thereby inhibiting cell growth (Figure 7G and
K) but, as expected, not in KARPAS-299 cells (Figure 7K
and H). Taken together, these findings demonstrate that
miR-497 controls multiple targets that collaborate to regu-
late cell cycle progression and cell growth.
ALK-positive cells are responsive to CDK4/6 inhibitors
The new generation of selective CDK4/6 inhibitors,
with anti-proliferative activity in Rb-proficient cells, target
tumor types in which CDK4/6 has a pivotal role in the G1-
to-S-phase cell cycle transition with improved effective-
ness and fewer adverse effects. Palbociclib is an orally
bioavailable CDK4/6 inhibitor recently approved by the
US Food and Drug Administration for the treatment of
metastatic breast cancer.32 As all three NPM-ALK+ cell
lines, SU-DHL1, COST and KARPAS-299 expressed
CDK4, CDK6 and Rb (Online Supplementary Figure S4), we
evaluated the effect of palbociclib treatment. We observed
that all NPM-ALK+ cell lines are sensitive to this molecule
(Figure 8A, E and I). In addition, we showed that palboci-
clib markedly inhibited the proliferation of NPM-ALK+
cells through the induction of G0/G1 cell-cycle arrest
(Figure 8B, F and J), increased apoptosis (Figure 8C, G and
K) and  reduced cell growth (Figure 8D, H and L). As a con-
trol of palbociclib efficacy, we observed a decrease in
Cdk4/6-specific phosphorylation of the Rb protein as
shown by Western blotting (Online Supplementary Figure
S10A). Densitometric analysis of the mean relative inten-
sity for pRB and RB corroborate Western blotting  results
(Online Supplementary Figure S10B). As palbociclib is a
selective cyclin D kinase 4/6 inhibitor, NPM-ALK+ ALCL
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Figure 8. Anaplastic lymphoma kinase (ALK)-positive(+) lymphoma cells are sensitive to CDK6 inhibitor. NPM-ALK+ ALCL SU-DHL1 (A-D), COST (E-H) and KARPAS-
299 (KARPAS) (I-L) cells were treated or not (H2O) with palbociclib, an CDK4/6 inhibitor. Cell count at three different time points (0, 1, 2 days) (A, E and  I), cell cycle
distribution (B, F and  J), caspase 3/7 activity (C, G and K) and cell proliferation rate (D, H and  L) were measured. Data represent means±SEM (bars) from 3 inde-
pendent experiments. *P<0.05; **P<0.001; ***P<0.0001; ns: not significant; unpaired two-tailed Student’s t-test with Welch’s correction. Data represent
means±Standard Error of Mean  (bars) from 3 independent experiments, *P<0.05; **P<0.001; unpaired two-tailed Student’s t-test with Welch’s correction. 
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SU-DHL1, COST and KARPAS-299 cells were transfected
with either an irrelevant siRNA as the negative control (si-
CTL) or a siRNA targeting CDK4 mRNA. In order to
check whether the knockdown of gene expression had
been efficiently achieved, we performed qPCR to detect
the CDK4 mRNA (Online Supplementary Figure S11C, F and
I). As silencing of CDK4 does not reduce cell proliferation
in ALK+ lymphoma cells (Online Supplementary Figure
S11A, D and G), nor induce apoptosis (Online
Supplementary Figure S11B, E and H), we suggest that the
action of palbiciclib is only CDK6-dependent.
Based on our findings that CDK6, CCNE1 and E2F3 are
important for efficient proliferation of NPM-ALK+ ALCL
cells, we hypothesized that the highest level of expression
of these factors could be the most favorable for tumor
development and possibly affect chemotherapy effective-
ness. To test this hypothesis, we used qPCR to measure
the expression of   CDK6, CCNE1 and E2F3 in a cohort of
NPM-ALK+ primary ALCL samples (n=55) obtained from
chemotherapy-naive patients at diagnosis. Compared to
normal reactive lymph nodes (RLNs) (n=19) and despite
the presence of a mixed population of neoplastic and nor-
mal cells, we observed a significant CDK6, CCNE1 and
E2F3 gene overexpression in NPM-ALK+ samples (Online
Supplementary Figure S12A). In order to evaluate the clinical
significance of CCNE1, CDK6 and E2F3 overexpression,
first using linear regression, we derived a model based on
microarray data on expression levels of CCNE1, CDK6,
E2F3 genes in NPM-ALK+ samples (n=55). The samples
included NPM-ALK+ primary biopsies of patients who had
experienced early relapse and those without relapse after
three years of minimal follow up after chemotherapy cure.
By applying the formulae obtained from linear regression,
we derived a ‘score’ for each patient: score = (-0.08378 x
CDK6) + (-0.41269 x CCNE1) + (0.37893 x E2F3).
Secondly, a ROC  curve was generated from CCNE1,
CDK6, E2F3 genes-based score from 44 NPM-ALK+ ALCL
samples, including 8 adults and 36 children, for whom
event-free survival is known (Online Supplementary Figure
S12B). The cut-off value and Air Under Curve (AUC) val-
ues were determined as -0.038 and 0.65, respectively.
Based on the optimal cut-off points from the ROC curve,
patients were significantly categorized into two groups,
high (n=25) and low (n=14) CCNE1, CDK6, E2F3 expres-
sion (Online Supplementary Figure S12C and D). NPM-ALK+
ALCL patients with a low expression of CCNE1, CDK6,
E2F3 had a poor prognosis (P<0.046) (Online Supplementary
Figure S12C). Moreover, this trend can be observed for
high (n=14) and low (n=22) expression in NPM-ALK+ pedi-
atric ALCL  (Online Supplementary Figure S12D). In addi-
tion, for the same pediatric cases, we noted that CCNE1,
CDK6, E2F3 gene-based score was increased in relapsing
patients (n=23 vs. without relapse n=13) (Online
Supplementary Figure S12E). As all patients were treated
with chemotherapy following diagnosis, our data suggest
that CDK4/6 inhibitors could benefit ALK+ patients har-
boring resistant tumors.
Discussion
MiR-195 and miR-497 are important members of the
miR-15/16 family and are aberrantly expressed in multiple
diseases, such as solid cancers.23,33 Based on the expression
of miRNAs, Steinhilber et al. have identified a gene signa-
ture including reduced expression of some miR-15/16
family members, such as miR-16, miR-195 and miR-497
that distinguish ALK+ from ALK– ALCL.34 Except miR-16,19
the functional characterization of miR-195 and miR-497,
which are clustered on chromosome 17p13.1, has never
been undertaken in ALK+ lymphoma cells.
MiR-195 and miR-497 downregulation has been consis-
tently demonstrated in a variety of solid tumor types.
miRNA-silencing in cancer is frequently related to abnor-
mal promoter methylation.35  Accordingly, the downregu-
lation of miR-195 and miR-497 has been reported to be
linked to promoter-associated hypermethylation in solid
cancers; demethylation following 5-aza-CdR treatment
resulted in the re-expression of these two miRNAs.36,37   In
the present work, we demonstrate for the first time that
miR-195 and miR-497 are down-regulated in human
NPM-ALK+ ALCL tissues and cell lines through a mecha-
nism involving NPM-ALK and DNA hypermethylation.
These results are highly reminiscent of what we previous-
ly observed for three other miRNA genes, MIR29A,
MIR125B and MIR150, the levels of which were also
reduced in NPM-ALK+ ALCL as a consequence of the pro-
moter hypermethylation.17,20,21 In addition, we observed
that only ectopic expression of miR-497 markedly attenu-
ates in vitro cell proliferation of NPM-ALK+ cells.
It is estimated that more than half of human genes are
targeted by at least one miRNA. One miRNA may have
multiple different mRNA targets and at the same time, one
mRNA might be targeted by multiple miRNAs. miR-497
regulates the expression of a plethora of targets, which are
involved in cell cycle, apoptosis, proliferation, etc.23 Recent
studies have revealed that miR-497 can directly reduce the
CCNE1 protein level to suppress tumor growth by induc-
ing G1 arrest in breast cancer38 and hepatocellular carcino-
ma.39 Indeed, CCNE1 protein binds to and activates cyclin-
dependent kinase 2 (CDK2) to promote a cascade of
events required for  cell-cycle progression from G1 to S
phase. Several other genes encoding cell-cycle regulators,
including Cyclin D1/CCND1 and Cyclin D3/CCND3,
Cyclin-dependent kinase 4 (CDK4) and CDK6, cell-cycle
division factors CDC25A and/or E2F3 transcription factor,
are also known targets of miR-497.23,40  The role of miR-497
in human cancer is not yet clear. Several studies have
reported that increased miR-497 expression via miR-497
mimic transfection suppressed proliferation and increased
apoptosis in various solid cancers, such as adrenocortical
carcinoma41 and pancreatic cancer.42 Accordingly, miR-497
overexpression was found to block G0/G1 phase transi-
tion in breast cancer cells43 and induce G1/S arrest in gas-
tric cancer cells.37 In our study, we revealed for the first
time that enhanced miR-497 expression in human NPM-
ALK+ lymphoma cells could suppress cell proliferation, by
inducing cell cycle arrest, and inhibit tumor growth in vivo.
These biological effects are the consequence of simultane-
ous downregulation of three mir-497 mRNA targets:
CCNE1, E2F3 and CDK6, and their subsequent decreased
protein level. Contribution of CCNE1 and E2F3 in uncon-
trolled cell-cycle progression and oncogenesis have never
been studied in human NPM-ALK+ ALCL models. Of note,
only two publications report an abnormal CDK6 expres-
sion in human NPM-ALK+ lymphoma cells. The amplifica-
tion of the CDK6 locus in NPM-ALK+ SU-DHL1 cells and
co-expression of high levels of CDK6 and CD31 (angio-
genic marker) in NPM-ALK+ ALCL samples have been
reported.31,44 
CDK4/CDK6 inhibitors in ALK-positive lymphomas
haematologica | 2019; 104(2) 357
NPM-ALK+ ALCL is a rare disease which accounts for
about 1-2% of adult non-Hodgkin lymphomas (NHL) and
10-15% of childhood NHL. The prognosis of NPM-ALK+
ALCL is better than that of other T-cell lymphomas.
Overall, patients with NPM-ALK+ ALCL who are resistant
to primary chemotherapy or who relapse early have the
worst prognosis.4,45 We checked the CCNE1, E2F3 and
CDK6 overexpression in a cohort of NPM-ALK+ primary
ALCL samples obtained from chemotherapy-naive
patients at diagnosis. As aberrant growth control is a hall-
mark of cancer cells, we hypothesized that altered
CCNE1, E2F3 and CDK6 expression in NPM-ALK+
patients could affect their response to treatment. Using a
NPM-ALK+ cohort, including patients who had experi-
enced early relapse after chemotherapy, we show that the
three G1-S regulators together could predict treatment
outcome in pediatric patients.  
CDK6 protein is a member of the cyclin-dependent
kinase family, which includes CDK4, with a 71% shared
amino acid identity. These homologs are ubiquitously
expressed and have largely overlapping functions. In mam-
malian cells, cell cycle is regulated by CDK4 and CDK6 in
early G1 phase through interactions with cyclins D1, D2
and D3. Cyclin D/CDK4 and cyclin D/CDK6 complexes
induce phosphorylation of the retinoblastoma protein (Rb)
and the release of E2F3 transcription factor from RB-E2F3
complexes. Cell-cycle components, such as CDK4 and
CDK6, are frequently altered in human cancer, reflecting
the deregulated growth of transformed cells. In B-cell lym-
phoid malignancies, DNA hypermethylation-mediated
epigenetic silencing of the tumor suppressors miR-124a
and miR-29 results in an upregulation of their target
CDK6.46 Downregulation of CDK6 was observed follow-
ing introduction of miR-29a mimics into T-cell acute lym-
phoblastic leukemia Jurkat cells.47 CDK6 has also been
implicated in thymic lymphoma formation in a transgenic
mouse model.48 Moreover, Kollmann et al. have observed
that NPM-ALK– transgenic mice lacking CDK6 expression
developed disease with a significantly prolonged latency.44
At the same time, in a NOD/SCID xenograft human mul-
tiple myeloma model, palbociclib, a newly developed
small-molecule inhibitor specific to CDK4 and CDK6, can
enhance the killing of myeloma cells by dexamethasone.49
In addition, palbociclib inhibits CDK4/6 activity according
to the activation status of cycling primary bone marrow
myeloma cells freshly isolated from both new and
relapsed patients.49 A phase II study has shown that pro-
gression-free survival was doubled with palbociclib plus
standard hormone therapy in advanced hormone receptor-
positive, HER2-negative breast cancer.32 Taken together,
these findings provide the grounds for new therapeutic
strategies in NPM-ALK+ ALCL either targeting the epige-
netic regulation of miRNAs and/or directly targeting the
CDK6 pathway. We have previously reported that
hypomethylating drugs may benefit NPM-ALK+ patients.17
Bonvini et al. previously described the effect of flavopiri-
dol, a pan-CDK inhibitor, on NPM-ALK+ ALCL cells.50  In
the present study, as a proof of concept, we have present-
ed in vitro data showing that palbociclib can be the first
promising and specific inhibitor for therapeutic targeting
of Cdk4/6 in NPM-ALK+ lymphoma cells. Our work also
provides a rationale for targeting ALK+ ALCL progression
with palbociclib. Indeed, it could be possible to achieve
greater synergy by combining palbociclib with other cyto-
toxic agents or anti-ALK tyrosine kinase inhibitor such as
crizotinib, recently approved for the treatment of metasta-
tic and late-stage ALK-rearranged non-small-cell lung can-
cers (NSCLC). In summary, these findings suggest that
CDK4/CDK6 inhibitors could be novel candidates for
mechanism-defined combination therapy in ALK+ lym-
phomas and possibly other ALK+-cell cancers including a
proportion of NSCLC.  
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